Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States

PURPOSE: Estimate the budget impact of belantamab mafodotin (belamaf) for patients with relapsed/refractory multiple myeloma (RRMM) who have received ≥4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. METHODS: A budget impact analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Anshul, Tosh, Jonathan C, Ambavane, Apoorva, Nikolaou, Andreas, Hogea, Cosmina, Samyshkin, Yevgeniy, Gorsh, Boris, Maiese, Eric M, Wang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439970/
https://www.ncbi.nlm.nih.gov/pubmed/34531667
http://dx.doi.org/10.2147/CEOR.S310619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439970/
https://www.ncbi.nlm.nih.gov/pubmed/34531667
http://dx.doi.org/10.2147/CEOR.S310619

Ejemplares similares